FDA Revises Equivalence Criteria For Generic Drug Approval

Law360, New York (December 4, 2013, 5:10 PM EST) -- The U.S. Food and Drug Administration on Wednesday revised its recommendations for how generic-drug makers can prove that their products are released into the human body in the same manner as brand-name counterparts, issuing high-level guidance covering an array of approaches.

In its draft guidance, the FDA spelled out general study characteristics to determine so-called bioequivalence. That refers to how fast and how much of an active ingredient shows up at the area of a person’s body where it’s intended to work.

Separate guidance is coming...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.